Table 3. Anti-HPV GMTs at different study time points (LU*; 95% CI; ATP analysis).
| GMTs | 6 mo after 1st dose of qHPV vaccine** | 1 mo after 2nd dose of qHPV vaccine | 36 mo after 2nd dose of qHPV vaccine | ||
|---|---|---|---|---|---|
| Group Co-adm n = 207 |
Group Co-adm n = 207 |
Group Sep n = 199 |
Group Co-adm n = 182 |
Group Sep n = 177 |
|
| Anti-HPV 6 | 11 (10–14) |
1103 (989–1230) |
1220 (1094–1362) |
77 (66–91) |
85 (72–101) |
| Anti-HPV 11 | 71 (62–81) |
3897 (3575–4248) |
4136 (3773–4533) |
308 (268–353) |
336 (291–388) |
| Anti-HPV 16 | 42 (36–49) |
3287 (2977–3628) |
3543 (3224–3893) |
286 (243–336) |
330 (283–384) |
| Anti-HPV 18 | 12 (10–14) |
887 (791–994) |
993 (890–1109) |
45 (37–55) |
60 (50–71) |
*
LU- Luminex Units; **qHPV vaccine - Gardasil®